Alzheimer’s Association Welcomes U.S. FDA Approval of Kisunla (donanemab)

CHICAGO, July 2, 2024 /PRNewswire/ — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive…